Mycosis Fungoides (MF)
Mycosis fungoides (MF) accounts for about half of all primary cutaneous lymphomas and is the most common type of cutaneous T-cell lymphoma (CTCL). The majority of MF cases are indolent, but approximately 35% of MF individuals may progress to involve extracutaneous organs. Our company is well-equipped to address your drug and therapy development requirements in mycosis fungoides therapy.
Background of Mycosis Fungoides
Mycosis fungoides is the most common type of primary cutaneous T-cell lymphoma, known for its chronic, indolent progression and tendency to begin as skin lesions before potentially advancing to more severe stages. Its incidence varies, but generally it is estimated to have an annual incidence of around 0.3 to 0.5 per 100,000 individuals, with a higher incidence reported in some studies.
Pathogenesis of Mycosis Fungoides
Mycosis fungoides, the most common type of cutaneous T-cell lymphoma, originates from malignant T cells that have a pronounced tendency to migrate to and remain within the skin. The disease's pathogenesis involves the clonal proliferation and buildup of these malignant T cells in the skin, lymph nodes, and peripheral blood. It is marked by intricate interactions between the T cells and the immune system, with the T cells maintaining abnormal yet similar functions to their normal physiological roles.
Fig. 1 Mycosis Fungoides: A Cancer of Skin-Homing T Cells. (Girardi, M., et al., 2004)Diagnosis Development of Mycosis Fungoides
- T-cell Receptor (TCR) Gene Rearrangement: Polymerase chain reaction (PCR) can detect clonal T-cell populations, aiding in distinguishing mycosis fungoides (MF) from benign inflammatory dermatoses that appear histologically similar.
- High-Throughput Sequencing (HTS): HTS provides a more sensitive and detailed analysis of TCR rearrangements compared to traditional PCR methods. RCM can identify the presence of atypical lymphocytes and their distribution within the skin layers.
- Gene Expression Profiling: The use of microarrays to analyze gene expression profiles in skin biopsies has been investigated as a method to differentiate mycosis fungoides from other inflammatory skin diseases.
Therapy Development of Mycosis Fungoides
Among small molecule drugs, Histone Deacetylase Inhibitors such as Vorinostat and Romidepsin function by altering gene expression to induce cancer cell death. Alisertib, a kinase inhibitor that targets Aurora A kinase, is being investigated for its potential to stop malignant cell division.
In gene therapy, advanced techniques such as CRISPR/Cas9 are being explored to correct genetic abnormalities in mycosis fungoides (MF). Additionally, gene silencing through siRNA aims to reduce malignant proliferation by targeting overexpressed genes.
In the realm of cell therapies, T-Cell Receptor therapy and CAR-T cell therapy are being explored, with the latter involving engineering T-cells to target CD30, a molecule often found on MF cells.
Monoclonal antibodies such as Alemtuzumab target CD52 to eliminate lymphocytes, while Mogamulizumab targets CCR4 to enhance immune responses against cancer cells by removing immunosuppressive Tregs.
Our Services
Our company adopts a partnership-driven approach. We collaborate closely with clients to craft tailored, innovative mycosis fungoides therapy strategies and ensure robust support throughout the process.
Platforms of Mycosis Fungoides Therapy Development
Animal Models of Mycosis Fungoides
We have established expertise in developing and utilizing relevant animal models that closely mimic the disease characteristics and response to therapy. These models enable us to evaluate the safety and efficacy of potential therapies.
| Non-Genetically Engineering Models | ||
| We provide diverse model choices customized to meet specific research needs related to mycosis fungoides. These models allow researchers to simulate and study the complex biological processes associated with mycosis fungoides. | ||
| Chemical Induced Models | ||
| Optional Models |
|
|
| Xenograft Models | ||
| Optional Models |
|
|
| Genetically Engineered Models | ||
| Our expertise in genetic engineering techniques, such as CRISPR/Cas9 technology, allows us to generate accurate and reliable models that recapitulate the genetic alterations observed in human mycosis fungoides. | ||
| Optional Models |
|
|
| Optional Species | Mice, Rats, Non-human primates, Others | |
In addition to these models, our comprehensive services encompass other models that target specific signaling pathways and molecular targets.
If our services align with your goals, please contact us for more details.
References
- Girardi, M., et al., "The pathogenesis of mycosis fungoides." N Engl J Med, (2004). 350(19): p. 1978-1988.
- Roccuzzo, G., et al., "Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice." Clin Cosmet Investig Dermatol, (2022). 15: p. 1899-1907.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.